| Style | Citing Format |
|---|---|
| MLA | Mohammadi A, et al.. "Alps-Like Disorder Linked With Stat3 Mutation: De Novo Variant With Bicytopenia and Literature Review." Endocrine, Metabolic and Immune Disorders - Drug Targets, vol. 26, no. , 2026, pp. -. |
| APA | Mohammadi A, Esfahani Z H, Abolhassani H, Sharafian S, Haghi S, Rezaei N, Yazdani R, Tavakol M (2026). Alps-Like Disorder Linked With Stat3 Mutation: De Novo Variant With Bicytopenia and Literature Review. Endocrine, Metabolic and Immune Disorders - Drug Targets, 26(), -. |
| Chicago | Mohammadi A, Esfahani Z H, Abolhassani H, Sharafian S, Haghi S, Rezaei N, Yazdani R, Tavakol M. "Alps-Like Disorder Linked With Stat3 Mutation: De Novo Variant With Bicytopenia and Literature Review." Endocrine, Metabolic and Immune Disorders - Drug Targets 26, no. (2026): -. |
| Harvard | Mohammadi A et al. (2026) 'Alps-Like Disorder Linked With Stat3 Mutation: De Novo Variant With Bicytopenia and Literature Review', Endocrine, Metabolic and Immune Disorders - Drug Targets, 26(), pp. -. |
| Vancouver | Mohammadi A, Esfahani Z H, Abolhassani H, Sharafian S, Haghi S, Rezaei N, et al.. Alps-Like Disorder Linked With Stat3 Mutation: De Novo Variant With Bicytopenia and Literature Review. Endocrine, Metabolic and Immune Disorders - Drug Targets. 2026;26():-. |
| BibTex | @article{ author = {Mohammadi A and Esfahani Z H and Abolhassani H and Sharafian S and Haghi S and Rezaei N and Yazdani R and Tavakol M}, title = {Alps-Like Disorder Linked With Stat3 Mutation: De Novo Variant With Bicytopenia and Literature Review}, journal = {Endocrine, Metabolic and Immune Disorders - Drug Targets}, volume = {26}, number = {}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Mohammadi A AU - Esfahani Z H AU - Abolhassani H AU - Sharafian S AU - Haghi S AU - Rezaei N AU - Yazdani R AU - Tavakol M TI - Alps-Like Disorder Linked With Stat3 Mutation: De Novo Variant With Bicytopenia and Literature Review JO - Endocrine, Metabolic and Immune Disorders - Drug Targets VL - 26 IS - SP - EP - PY - 2026 ER - |